High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.

Autor: Hollis RL; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK. Electronic address: robb.hollis@ed.ac.uk., Elliott R; Edinburgh Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK., Dawson JC; Edinburgh Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK., Ilenkovan N; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK; Cancer Research UK Scotland Institute, Glasgow, UK., Matthews RM; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK., Stillie LJ; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK; Cancer Research UK Scotland Institute, Glasgow, UK., Oswald AJ; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK., Kim H; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada., Llaurado Fernandez M; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada., Churchman M; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK., Porter JM; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK., Roxburgh P; Cancer Research UK Scotland Institute, Glasgow, UK; CRUK Scotland Centre, School of Cancer Sciences, Glasgow, UK., Unciti-Broceta A; Edinburgh Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK., Gershenson DM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Herrington CS; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK., Carey MS; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada., Carragher NO; Edinburgh Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK., Gourley C; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 Jul; Vol. 186, pp. 42-52. Date of Electronic Publication: 2024 Apr 05.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.

Autor: Herrington CS; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Oswald AJ; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Stillie LJ; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; Cancer Research UK Scotland Centre and Cancer Research UK Beatson Institute, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Croy I; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Churchman M; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Hollis RL; The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. robb.hollis@ed.ac.uk.

Publikováno v: British journal of cancer [Br J Cancer] 2024 Feb; Vol. 130 (2), pp. 327-335. Date of Electronic Publication: 2023 Dec 14.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.

Autor: Oswald AJ; University of Edinburgh, Edinburgh, Scotland, UK. ailsa.oswald@ed.ac.uk., Symeonides SN; University of Edinburgh, Edinburgh, Scotland, UK., Wheatley D; Royal Cornwall Hospital, Truro, Cornwall, England, UK., Chan S; Nottingham University Hospitals NHS Trust, Nottingham, England, UK., Brunt AM; University Hospitals of North Midlands NHS Trust, Stoke-On-Trent & University of Keele, Staffordshire, England, UK., McAdam K; Peterborough City Hospital, Peterborough, England, UK., Schmid P; Barts Cancer Institute, London, England, UK., Waters S; Velindre Hospital, Whitchurch, Cardiff, Wales, UK., Poole C; University Hospitals Coventry & Warwickshire, Coventry, England, UK., Twelves C; University of Leeds and St James' Hospital, Leeds, England, UK., Perren T; University of Leeds and St James' Hospital, Leeds, England, UK., Bartlett J; University of Edinburgh, Edinburgh, Scotland, UK., Piper T; University of Edinburgh, Edinburgh, Scotland, UK., Chisholm EM; Scottish Clinical Trials Research Unit, Edinburgh, Scotland, UK., Welsh M; Scottish Clinical Trials Research Unit, Edinburgh, Scotland, UK., Hill R; Scottish Clinical Trials Research Unit, Edinburgh, Scotland, UK., Hopcroft LEM; Scottish Clinical Trials Research Unit, Edinburgh, Scotland, UK., Barrett-Lee P; Velindre Cancer Centre, Cardiff, Wales, UK., Cameron DA; University of Edinburgh, Edinburgh, Scotland, UK.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 May; Vol. 199 (1), pp. 35-46. Date of Electronic Publication: 2023 Mar 02.